交易中 10-02 11:39:47 美东时间
-0.225
-0.54%
Biotech could be entering a broader re-rating as artificial intelligence and genomics accelerate drug discovery, while health care valuations remain at a significant discount to the broader market, according to David Song, MD, Ph.D., CFA and investment partner at Tema ETFs. "Biotech is already in th...
09-04 06:14
https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305
05-28 04:14